Community-acquired pneumonia in the elderly.

CAP is traditionally considered a medical disease, and is managed with intravenous fluids and antibiotics on medical floors. Recent cost-containment efforts have shifted the provision of care to the outpatient settings, and only those with most severe disease and multiple comorbid illnesses are admitted to hospitals. Therefore, the proportion of hospitalized patients with severe CAP that need intensive care and life support is increasing. Furthermore, the incidence of severe CAP is also rising due to disproportionate growth of the elderly population that is most vulnerable to this deadly disease. Many of these elderly patients have advanced underlying diseases, and CAP might often be a terminal event superimposed on an underlying chronic debilitating illness. As ICU physicians, we need to be familiar with this disease, its complications, and its prognosis to provide intensive care in a timely and rational fashion in some patients, and refrain from life support in others. Just as prior efforts have sought to improve and standardize criteria for hospital admission, future efforts should aim to improve and standardize decisions regarding intensive care and life support in these very sick elderly patients. Future efforts in the management of CAP need to consider the postdischarge period where most deaths occur. Prevention is an important issue especially for those at high risk for CAP.

[1]  R. Light,et al.  Parapneumonic effusions. , 1980, The American journal of medicine.

[2]  J. Bartlett,et al.  Community‐Acquired Pneumonia: Impact of Immune Status , 1996, American journal of respiratory and critical care medicine.

[3]  A. Fein,et al.  Pneumonia in the elderly. Special diagnostic and therapeutic considerations. , 1994, The Medical clinics of North America.

[4]  M. Kolczak,et al.  Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. , 2000, The New England journal of medicine.

[5]  Gilles Clermont,et al.  Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. , 2002, American journal of respiratory and critical care medicine.

[6]  W. Kapoor,et al.  New and Emerging Etiologies for Community‐Acquired Pneumonia with Implications for Therapy: A Prospective Multicenter Study of 359 Cases , 1990, Medicine.

[7]  R. Estruch,et al.  Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. , 1997, American journal of respiratory and critical care medicine.

[8]  W. Mower,et al.  Effect of routine emergency department triage pulse oximetry screening on medical management. , 1995, Chest.

[9]  J. Macfarlane,et al.  2004 update of BTS pneumonia guidelines: what’s new? , 2004, Thorax.

[10]  M. Leinonen,et al.  Chlamydia pneumoniae community-acquired pneumonia: A review of 62 hospitalized adult patients , 1996, Infection.

[11]  J. Macfarlane,et al.  Early management of younger adults dying of community acquired pneumonia. , 1993, Respiratory medicine.

[12]  R. Breiman,et al.  Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. , 1996, JAMA.

[13]  E. Kramarow,et al.  Health, United States, 1999; with health and aging chartbook , 1999 .

[14]  D. Coakley,et al.  Prospective hospital study of community acquired lower respiratory tract infection in the elderly. , 1991, Respiratory medicine.

[15]  J. Córdoba-Doña,et al.  Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Thebritishthoracicsocietyrese,et al.  The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service. , 1992, Respiratory medicine.

[17]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[18]  P. Mäkelä,et al.  Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. , 1999, Archives of internal medicine.

[19]  T. Marrie,et al.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  T. Marrie,et al.  Nursing Home‐Acquired Pneumonia: A Case‐Control Study , 1986, Journal of the American Geriatrics Society.

[21]  K. Cartwright,et al.  Rapid Diagnosis of Bacteremic Pneumococcal Infections in Adults by Using the Binax NOW Streptococcus pneumoniae Urinary Antigen Test: a Prospective, Controlled Clinical Evaluation , 2003, Journal of Clinical Microbiology.

[22]  A. Porath,et al.  Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients. , 1996, Respiration; international review of thoracic diseases.

[23]  A. Porath,et al.  Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. , 1997, Age and ageing.

[24]  T. Marrie,et al.  Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. , 2003, Archives of internal medicine.

[25]  C. Berg,et al.  Abortion surveillance--United States, 1999. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[26]  D. Soldo,et al.  GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS , 2017 .

[27]  V. Yu,et al.  Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia , 1993, The Lancet.

[28]  F. Rodríguez de Castro,et al.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome , 2004, Thorax.

[29]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[30]  T. Marrie,et al.  A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. , 2000, JAMA.

[31]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[32]  J. Rello,et al.  Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Torres,et al.  Viral community-acquired pneumonia in nonimmunocompromised adults. , 2004, Chest.

[34]  D. Kaiser,et al.  Clinical effectiveness of influenza vaccination in Manitoba. , 1993, JAMA.

[35]  M. Fisch,et al.  Predicting death in patients hospitalized for community-acquired pneumonia. , 1991, Annals of internal medicine.

[36]  S. Kivelä,et al.  Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. , 1996, Archives of internal medicine.

[37]  O. Sacristán,et al.  Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. , 2001, Archives of internal medicine.

[38]  M. Elliott,et al.  Non-invasive Positive Pressure Ventilation , 1999, Journal of the Royal College of Physicians of London.

[39]  E. Ely,et al.  Six-month neuropsychological outcome of medical intensive care unit patients , 2003, Critical care medicine.

[40]  D. Schwartz,et al.  Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[42]  M. Niederman,et al.  The cost of treating community-acquired pneumonia. , 1998, Clinical therapeutics.

[43]  R. Briggs,et al.  Raised respiratory rate in elderly patients: a valuable physical sign. , 1982, British medical journal.

[44]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  M. Leinonen,et al.  role of serum troponin levels combined with electrocardiographic findings Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines , 2001 .

[46]  R. Rodríguez-Roisín,et al.  Severe community-acquired pneumonia. Epidemiology and prognostic factors. , 1991, The American review of respiratory disease.

[47]  S. Ewig,et al.  Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. , 1999, The European respiratory journal.

[48]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[49]  C. Sirio,et al.  Long-term mortality and quality of life after prolonged mechanical ventilation* , 2004, Critical care medicine.

[50]  I. Bolíbar,et al.  Risk factors for community-acquired pneumonia in adults: a population-based case-control study. , 1999, The European respiratory journal.

[51]  G. Bernard,et al.  Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  J. Macfarlane,et al.  HOSPITAL STUDY OF ADULT COMMUNITY-ACQUIRED PNEUMONIA , 1982, The Lancet.

[53]  L. Mandell,et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  A. Torres,et al.  Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. , 1999, American journal of respiratory and critical care medicine.

[55]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[56]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[57]  D. Schoenfeld,et al.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[58]  M. Trabucchi,et al.  Is pneumonia still the old man's friend? , 2003, Archives of internal medicine.

[59]  Benjamin A Lipsky,et al.  Diagnosing pneumonia by physical examination: relevant or relic? , 1999, Archives of internal medicine.

[60]  K. Steinberg,et al.  Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. , 1995, JAMA.

[61]  D. Snydman,et al.  Influence of blood culture results on antibiotic choice in the treatment of bacteremia. , 1994, Archives of internal medicine.

[62]  M. Niederman,et al.  Severe community-acquired pneumonia. Assessment of severity criteria. , 1998, American journal of respiratory and critical care medicine.

[63]  D. Kaiser,et al.  Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. , 1989, Thorax.

[64]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[65]  D M Fleming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. , 1997, The New England journal of medicine.

[66]  P. Francioli,et al.  Community-Acquired Pneumonia: A Prospective Outpatient Study , 2001, Medicine.

[67]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[68]  M. Fine,et al.  Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. , 1998, Annals of emergency medicine.

[69]  K. Nichol,et al.  The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. , 1999, Archives of internal medicine.

[70]  J. Bartlett,et al.  Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. , 2004, Archives of internal medicine.

[71]  Y. Ong,et al.  Aetiology and outcome of severe community-acquired pneumonia in Singapore. , 1998, The European respiratory journal.

[72]  L. Brammer,et al.  Influenza surveillance--United States, 1992-93 and 1993-94. , 1997, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[73]  A. Monto,et al.  Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. , 2002, The Journal of infectious diseases.

[74]  M. Kollef,et al.  The use of noninvasive positive pressure ventilation in the emergency department: results of a randomized clinical trial. , 1998, Chest.

[75]  S. Soimakallio,et al.  Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. , 1993, American journal of epidemiology.

[76]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[77]  E. Manor,et al.  Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. , 1996, Thorax.

[78]  A. Bourdin,et al.  Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor , 2004, European Respiratory Journal.

[79]  R. Rodríguez-Roisín,et al.  Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. , 1996, American journal of respiratory and critical care medicine.

[80]  A. Monto,et al.  Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.

[81]  J. de Batlle,et al.  Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. , 1997, American journal of respiratory and critical care medicine.

[82]  M. Leinonen,et al.  Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. , 1999, Vaccine.

[83]  F. Tubau,et al.  The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. , 2002, The American journal of medicine.

[84]  S. Sahn Management of complicated parapneumonic effusions. , 1993, The American review of respiratory disease.

[85]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[86]  M. Cooney,et al.  Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. , 1979, JAMA.

[87]  R. Venezia,et al.  Vancomycin and Oxacillin Synergy for Methicillin-Resistant Staphylococci , 2000, Antimicrobial Agents and Chemotherapy.

[88]  A. Detsky,et al.  Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. , 1994, Archives of internal medicine.

[89]  J. Gladman,et al.  A hospital study of community acquired pneumonia in the elderly. , 1990, Thorax.

[90]  A. Torres,et al.  Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. , 1999, American journal of respiratory and critical care medicine.

[91]  Introduction to Table V. Premature deaths, monthly mortality, and monthly physician contacts--United States. , 1982, MMWR. Morbidity and mortality weekly report.

[92]  Brown Rb Community-acquired pneumonia: diagnosis and therapy of older adults. , 1993 .

[93]  M. Luquin,et al.  Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain , 1988, European Journal of Clinical Microbiology and Infectious Diseases.

[94]  P. Ward,et al.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. , 2000, JAMA.

[95]  M. Woodhead,et al.  Aetiology and outcome of severe community-acquired pneumonia. , 1985, The Journal of infection.

[96]  J. Rello,et al.  Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  I. Suramo,et al.  High-resolution computed tomography for the diagnosis of community-acquired pneumonia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[98]  N. Cox,et al.  Prevention and control of influenza , 1999, The Lancet.

[99]  J. Michel,et al.  Community‐Acquired Pneumonia in Older Patients , 1996, Journal of the American Geriatrics Society.

[100]  M. Niederman,et al.  Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. , 2002, Archives of internal medicine.

[101]  P. Ward,et al.  Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. , 2004, The Journal of infectious diseases.

[102]  A. Blainey,et al.  Causes of pneumonia presenting to a district general hospital. , 1981, Thorax.

[103]  P. Coll,et al.  Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. , 1993, The European respiratory journal.

[104]  T. Marrie,et al.  Epidemiology of community-acquired pneumonia in the elderly. , 1990, Seminars in respiratory infections.

[105]  R. Brown Community-acquired pneumonia: diagnosis and therapy of older adults. , 1993, Geriatrics.

[106]  A. El‐Solh,et al.  Colonization of dental plaques: a reservoir of respiratory pathogens for hospital-acquired pneumonia in institutionalized elders. , 2004, Chest.

[107]  T. Harrison,et al.  Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. , 2001, Journal of medical microbiology.

[108]  G. Clermont,et al.  Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. , 2002, American journal of respiratory and critical care medicine.

[109]  A. Ma,et al.  Predicting bacteremia in patients with community-acquired pneumonia. , 2004, American journal of respiratory and critical care medicine.

[110]  B. Harrison,et al.  The outcome of community acquired pneumonia treated on the intensive care unit. , 1990, Respiratory medicine.

[111]  M. Elliott,et al.  Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome , 2001, Thorax.

[112]  S. Ho,et al.  Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. , 1994, Age and ageing.

[113]  W. Lim,et al.  A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. , 2001, The European respiratory journal.

[114]  T. Marrie,et al.  Community‐Acquired Pneumonia Requiring Hospitalization , 1985, Journal of the American Geriatrics Society.

[115]  C. Sirio,et al.  International comparisons of critical care outcome and resource consumption. , 1997, Critical care clinics.

[116]  M. Fine,et al.  Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. , 1990, The American journal of medicine.

[117]  A. Schuchat,et al.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.

[118]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[119]  J. Guest,et al.  Community-acquired pneumonia: the annual cost to the National Health Service in the UK. , 1997, The European respiratory journal.

[120]  R. Breiman,et al.  Prevention of pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997 .

[121]  J. Macfarlane,et al.  Impact of management guidelines on the outcome of severe community acquired pneumonia. , 1997, Thorax.

[122]  T. Marrie Community-acquired pneumonia in the elderly. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[124]  Sheldon P Stone,et al.  Community-acquired pneumonia , 1998, The Lancet.

[125]  T. Marrie,et al.  Community-acquired pneumonia requiring hospitalization: 5-year prospective study. , 1989, Reviews of infectious diseases.

[126]  J. A. Cuello,et al.  Severe community-acquired pneumonia. Etiology, prognosis, and treatment. , 1990, The American review of respiratory disease.

[127]  G. Dinant,et al.  Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. , 1993, BMJ.

[128]  J. R. Parsons,et al.  Bacteremia With Streptococcus pneumoniae: Implications for Therapy and Prevention , 1996 .

[129]  A J Moskowitz,et al.  Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. , 1997, JAMA.

[130]  J. Butler Cigarette smoking and invasive pneumococcal disease , 2000 .

[131]  E. Bigler,et al.  Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. , 1999, American journal of respiratory and critical care medicine.

[132]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[133]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[134]  J. Macfarlane,et al.  PROSPECTIVE STUDY OF THE AETIOLOGY AND OUTCOME OF PNEUMONIA IN THE COMMUNITY , 1987, The Lancet.

[135]  B. Lipworth,et al.  C-reactive protein. A clinical marker in community-acquired pneumonia. , 1995, Chest.

[136]  A. Ortqvist,et al.  Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. , 1985, Scandinavian journal of infectious diseases.

[137]  G. Town,et al.  Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. , 1996, Thorax.